BlinkLab LimitedASX: BB1

BB1 Presents at the World's Largest Neuroscience Conference

· Issued by BlinkLab Limited via ASX

Filed with ASX · · 3 pages · English

Summary by 6ix AI

The presentations highlighted objective measures that could aid in diagnosing autism and monitoring ADHD symptoms. The company aims to enhance clinical adoption of its products through increased visibility at this major neuroscience conference. BlinkLab's regulatory program for its diagnostic tool remains a priority, with an FDA submission expected soon.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

ASX:BB1 ASX:BB1 ASX Announcement 20 November 2026 BlinkLab Presents Digital Biomarker Data in Autism and ADHD at Neuroscience 2026, the World’s Largest Neuroscience Conference Highlights ? Two data presentations at Neuroscience 2026: BlinkLab and its academic collaborators presented their autism...

BlinkLab Limited on 6ix

Earlier from BlinkLab

All BlinkLab news releases